Companies /Healthcare

Alumis Inc

NASDAQ: ALMS Biotechnology
$3.96
▼ $0.37 (−8.55%) today
Markets closed · 11:36pm ET

ALMS at a Glance

Valuation
Market cap
$562.1M
Profitability
Revenue (TTM)
$7.2M
EPS (TTM)
$-3.48
Price
52-week range
$4 – $31
Street target
$25.38

Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: ALMS alumis.com

About Alumis

Alumis Inc. is a late-stage biopharmaceutical company developing oral tyrosine kinase 2 (TYK2) inhibitors for immune-mediated, neuroinflammatory and neurodegenerative diseases, using a proprietary data analytics platform and precision approach.

Its lead candidate, envudeucitinib, is a highly selective oral TYK2 inhibitor that completed the Phase 3 ONWARD program in moderate-to-severe plaque psoriasis. An NDA submission is planned for 4Q 2026. Envudeucitinib was also studied in systemic lupus erythematosus in the Phase 2b LUMUS trial, which missed its endpoints overall but showed responses in IFNGS-high patients.

A second candidate, A-005, is a CNS-penetrant TYK2 inhibitor targeting conditions such as Parkinson's disease, with a Phase 2 biomarker trial planned for 2027. The pipeline also includes several preclinical programs.

Alumis currently earns collaboration revenue under a collaboration and licensing agreement with Kaken Pharmaceutical Co., Ltd. It previously completed a merger with ACELYRIN, Inc. Updated

ALMS Coverage

Frequently Asked Questions

What does Alumis do?

Alumis Inc. is a late-stage biopharmaceutical company developing oral tyrosine kinase 2 (TYK2) inhibitors for immune-mediated, neuroinflammatory and neurodegenerative diseases, using a proprietary data analytics platform and precision approach.

What is the ALMS stock price target?

The Wall Street consensus 12-month price target for ALMS is $25.38.